[{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10R","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10R","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10R","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ University of Oxford","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ University of Oxford"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Rimabotulinumtoxin B","moa":"SNAP25","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Supernus Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Supernus Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Levolta Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Zoledronic Acid Derivative","moa":"Bone resorption","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Levolta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Prisma Health-Midlands","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Astaxanthin","moa":"NF-kappa-B inhibitor alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Prisma Health-Midlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prisma Health-Midlands \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prisma Health-Midlands \/ Inapplicable"},{"orgOrder":0,"company":"Ashibio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Ashibio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashibio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ashibio \/ Inapplicable"},{"orgOrder":0,"company":"Ashibio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Ashibio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashibio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ashibio \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"National Institute for Health Research, UK | 180 Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ National Institute for Health Research, UK | 180 Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ National Institute for Health Research, UK | 180 Life Sciences"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"NIHR","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ NIHR","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ NIHR"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"180 Life Sciences \/ Celltrion","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Celltrion"},{"orgOrder":0,"company":"FG Brasil","sponsor":"3F Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"FG Brasil","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FG Brasil \/ 3F Clinical Trials","highestDevelopmentStatusID":"9","companyTruncated":"FG Brasil \/ 3F Clinical Trials"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Lantheus Medical Imaging | Rothman Institute","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Thomas Jefferson University \/ Lantheus Medical Imaging | Rothman Institute","highestDevelopmentStatusID":"9","companyTruncated":"Thomas Jefferson University \/ Lantheus Medical Imaging | Rothman Institute"},{"orgOrder":0,"company":"SPA - Antibiotic Products","sponsor":"Pharmaceutical Development and Services","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clodronic Acid Disodium Salt","moa":"Adenine nucleotide translocator 1 (SLC25A4)","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"SPA - Antibiotic Products","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPA - Antibiotic Products \/ Pharmaceutical Development and Services","highestDevelopmentStatusID":"9","companyTruncated":"SPA - Antibiotic Products \/ Pharmaceutical Development and Services"},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Amzell B.V","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amzell B.V \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Amzell B.V \/ Inapplicable"},{"orgOrder":0,"company":"Nature Cell Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Adipose Tissue-Derived Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Nature Cell Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nature Cell Co \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nature Cell Co \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : GS-5745 (andecaliximab) is a humanized antibody that specifically inhibits the matrix MMP-9 enzyme. It is being evaluated for the treatment of fibrodysplasia ossificans progressiva.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 23, 2025

                          Lead Product(s) : Andecaliximab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 18, 2024

                          Lead Product(s) : Andecaliximab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 16, 2024

                          Lead Product(s) : Clodronic Acid Disodium Salt

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Pharmaceutical Development and Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : The agreement aims for the commercialization of an investigational osteoarthritis (OA) therapy, VOLT01 (zoledronic acid), a patented novel combination drug, in the Middle East and Africa (MEA) region, excluding South Africa.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 06, 2023

                          Lead Product(s) : Zoledronic Acid Derivative

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Tabuk Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Adalimumab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, crohn's disease, and ankylosing spondylitis.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          December 23, 2022

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Alliance Global Partners

                          Deal Size : $6.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Research at Oxford University has indicated an anti-TNF mechanism of Adalimumab can slow or prevent the proliferation of myoblast cells that lead to the formation and growth of the fibrous nodules/cords in the palm and possible finger contracture.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          December 20, 2022

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Alliance Global Partners

                          Deal Size : $6.0 million

                          Deal Type : Public Offering

                          blank

                          07

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Adalimumab is an anti-TNF being developed for the treatment of early-stage dupuytren’s contracture. The MHRA reviewed the primary and secondary endpoints in the repurposing anti-TNF for treating dupuytren's disease (RIDD) trial.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 30, 2022

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 31, 2022

                          Lead Product(s) : Efgartigimod

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Approximately 50% of patients with Dupuytren’s disease treated with Adalimumab also have frozen shoulder and Professor Nanchahal has previously shown that that TNF, a pro-inflammatory protein, is a key driver of the fibrosis in early-stage Dupuytren’...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 22, 2022

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : NIHR

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Adalimumab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions, to treat early-stage Dupuytren’s disease.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 14, 2022

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank